Editor's key points † Conventional coagulation testing does not consider the impact of blood flow on platelet interactions with coagulation factors. † A flow chamber-based assay and thromboelastometry were used to study the effects of haemodilution and haemostatic factors on thrombus formation. † Haemodilution delayed thrombus formation, more so at the higher flow rate, with improvements produced by haemostatic agents in an agent-and a flow-dependent manner.
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Vascular haemostasis is achieved by complex physical and biochemical reactions of platelets and coagulation factors at the site of injury. 1 -3 In the presence of blood flow, platelet activation and coagulation processes are dynamically affected by local influx and efflux of platelets, coagulation factors, and inhibitors. 1 4 5 However, in vitro clinical evaluation of haemostatic function is performed under static conditions (shear rates ,0.1 s 21 ). 6 7 Isolated measurements of platelet count, plasma-based prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen level cannot be inferred to reflect overall haemostatic function in vivo. 8 -10 Platelet aggregation is normally tested in response to a single agonist in anticoagulated plasma or whole blood. 11 Therefore, complex interactions of multiple platelet agonists and coagulation factors with platelets in vivo cannot be assessed with conventional PT/aPTT or platelet aggregometry. In perioperative bleeding, the assessment of coagulopathy is further complicated by haemodilution, 12 13 which strongly influences dynamic interactions of erythrocytes, platelets, and coagulation factors under flow conditions. 14 -17 We hypothesized that overall haemostatic functions are differently influenced by haemodilution between low and high blood flow patterns (e.g. arteriole and artery). Therefore, we evaluated the effects of haemodilution and the procoagulant activities of various factor concentrates on thrombus formation in human whole blood using a microchip-based flow-chamber system 18 -20 in parallel with rotational thromboelastometry.
fibrinogen concentrate (RiaStap) were all obtained from CSL Behring (Marburg, Germany). The stock solution of Humate P contained factor VIII (FVIII) 70.0 U ml 21 and vWF 154.8 U ml 21 , and was used in our in vitro experiments to simulate the release of FVIII/vWF from endothelium that normally occurs in vivo during surgery and trauma. 21 22 Further, PCC (0.3 U ml 21 ) and fibrinogen concentrates (1-2 g litre 21 ) were added to diluted whole blood samples to model the replacement of vitamin K-dependent clotting factors and fibrinogen, respectively. 23 
Blood samples
The study was conducted according to a protocol approved by the local institutional review board (Emory University, Atlanta, Georgia, USA). For the first part of the study, blood samples were collected from 12 healthy volunteers (4 females and 8 males, age 27-61 yr) after informed written consents were obtained. These subjects had not taken medication(s) that affect platelet function or coagulation in the preceding 2 weeks. Whole blood samples were collected in 3.2% sodium citrate (Venoject IIw 4.5 ml; Terumo, Japan) with corn trypsin inhibitor (CTI; final concentration; 50 mg ml 21 ). They were immediately used for perfusion experiments. The whole blood sample for thromboelastometry was collected in 3.2% sodium citrate (Vacutainerw 4.5 ml; Beckton-Dickinson, Franklin Lakes, NJ, USA). For in vitro modelling of haemodilution, whole blood samples were diluted 6:4 v/v with normal saline (i.e. 40% volume replacement). Some of the 3.2% sodium citrate blood was immediately centrifuged at 2000×g for 20 min to obtain platelet-poor plasma. The plasma samples were stored at 2808C until batch analysis. For the second part of the study conducted to evaluate in vivo haemodilution, whole blood samples were collected from 15 consented patients undergoing cardiac surgery with cardiopulmonary bypass (CPB 
Laboratory measurements
Haematocrit (%) and platelet count were measured using the Coulter AcTanalyser (Coulter Corporation, Miami, FL, USA). Measurement of vWF, fibrinogen, PT, aPTT, prothrombin (FII), FVIII, and antithrombin (AT) levels was performed on a coagulation analyser (STA Compact, Diagnostica Stago, Parsippany, NJ, USA) using manufacturer's kits and directions. Fibrinogen concentrations were determined using the modified Clauss method.
Flow-chamber assay
Thrombus formation under flow was evaluated using the Total Thrombus Formation Analysis System (T-TAS; Fujimori Kogyo, Tokyo, Japan). 18 19 This newly developed microchip-based flow-chamber system is equipped with a rectangular capillary (width 300, depth 60 mm, and length 15 mm), pneumatic pump, video microscope, and flow pressure sensor (Fig. 1) .
Recalcified whole blood is perfused at 378C through the microcapillary chamber pre-coated with tissue factor and collagen. The flow pressure changes are monitored by the pressure transducer located upstream in the microcapillary. Thrombus formation or breakdown within the microcapillary alters resistance causing the pressure to increase or decrease, respectively. In the experiments under flow rates of 10 and 3 ml min 21 , initial shear rates against the microcapillary wall are calculated to be 1100 and 330 s 21 , respectively. These shear rates correspond to normal shear rate in arterioles and medium-sized arteries. 24 Whole blood was perfused at a flow rate of 10 or 3 ml min 21 before and after 40% dilution. For the latter, perfusion experiments were repeated after in vitro addition of (i) vWF, 1. Thrombus formation was monitored qualitatively by video microscopy, and was also quantified by the flow pressure changes in the capillary. The endpoint parameters of the flow pressure included the onset of thrombus formation (T on ; the onset of thrombus formation defined as the time to flow pressure of 5 kPa), and the time to 80 kPa (T 80 ; a parameter that reflects thrombus growth rate). 18 19 Thromboelastometry Changes in viscoelastic properties of whole blood clotting were evaluated using rotational thromboelastometry (TEM Systems, Inc., Durham, NC, USA). All measurements were performed at 378C. Coagulation was triggered in recalcified whole blood (300 ml mixed with 20 ml of 0.2 M CaCl 2 ) using tissue factor (EXTEM, TEM Systems, Inc.). The following thromboelastometric parameters were collected: clotting time (CT, s), which corresponds to the lag time before clotting; clot formation time (CFT, s), which reflects the initial rate of clot formation; maximum clot firmness (MCF, mm) as the maximal tensile strength of clot. 10 EXTEM measurements were obtained before and after 40% dilution. For the latter, EXTEM measurements were repeated after in vitro addition of (i) vWF, 1. Analysis of thrombus by confocal microscopy
The composition of thrombus formed in the flow chamber before and after the dilution was evaluated using immunostaining and confocal laser scanning microscopy. After completion of each perfusion, thrombus was carefully removed from the mid-segment of the capillary, washed three times with phosphate-buffered saline, and then incubated with fluorescein isothiocyanate (FITC)-conjugated mouse antihuman CD41 (platelet glycoprotein IIb) IgG (1:6 dilution) at room temperature for 15 min in the dark. FITC-conjugated mouse IgG was used as a control. After three washes with Trisbuffered saline containing 0.1% Triton X-100 (TBST), thrombus specimen was immobilized with OptiLyse C (Beckman Coulter, France) for 15 min at room temperature. After additional three washes with TBST, the sample was blocked for 1 h at room temperature with Block Ace (Yukijirushi, Japan) containing 1 mg 21 ml of normal goat IgG. Thereafter, the sample was incubated with rabbit anti-human fibrinogen IgG (1:99 dilution) labelled with Alexa 594 at room temperature for 30 min in the dark. Alexa 594-conjugated rabbit IgG was used as a control. The final specimens were examined using an LSM700 confocal microscope (Zeiss, Germany).
Western blot analysis
At the end of perfusion experiment, thrombus was recovered from the microchip, dissolved in 100 ml of 62.5 mM Tris -HCl, pH 6.8, 2.15% sodium dodecyl sulphate (SDS), 15% glycerol, 0.005% bromophenol blue, and boiled for 1 min. The sample was subjected to 10-20% SDS-polyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred to nitrocellulose membrane. The membrane was then incubated with a sheep anti-human thrombin (Affinity Biologicals, Ancaster, ON, Canada) or a rabbit anti-human fibrinogen antibody (AssayPro, St Charles, MO, USA). It was then washed extensively, and incubated with a horseradish peroxidase-linked secondary antibody. The signals were detected by enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA).
Flow-chamber assay and thromboelastometry in cardiac surgery patients
Additional flow-chamber experiments were performed to confirm our in vitro dilution model using whole blood from cardiac surgical patients. Perfusion experiments were performed in recalcified whole blood at baseline, and after CPB. PCC and fibrinogen concentrates represent major haemostatic interventions after CPB. 23 Plasma vWF level tends to remain normal or supra-normal during surgery. 25 The flow rate of 3 ml min 21 was thus chosen to evaluate procoagulant effects of PCC and fibrinogen, which are preferably demonstrated at a lower shear rate. 18 19 PCC and fibrinogen were added in vitro to post-CPB blood as follows: (i) PCC, 0.3 U ml 21 ; (ii) fibrinogen, 2 g litre 21 ; or (iii) combination of PCC, 0.3 U ml 21 and fibrinogen, 1 g litre 21 (all in final concentrations).
For thromboelastometry, EXTEM was measured at baseline and post-CPB. In post-CPB samples, EXTEM measurements were repeated after in vitro addition of PCC, fibrinogen, or their combination as in the above perfusion experiment. FIBTEM was also used for determining fibrin-specific clot firmness after fibrinogen replacement by inhibiting plateletfibrin(ogen) interactions using cytochalasin D. 
Morphological evaluation of thrombus formation
The qualitative analysis of normal thrombus formation by video microscopy (×200) demonstrated a time-dependent process that proceeds in both the capillary wall and the centre of the capillary (Fig. 2) . During perfusion at 10 ml min 21 , a small amount of thrombus was deposited over the capillary within 3-4 min. The development of intra-luminal thrombus was rapidly seen, and the capillary was occluded within 1-2 min after the initial appearance of thrombus ( Fig. 2A, control) . Deposition of thrombus during perfusion at 3 ml min 21 occurred similarly to perfusion at 10 ml min 21 , but general expansion of thrombus was observed more slowly .4-5 min (Fig. 2B, control) . After 40% dilution of whole blood, initial appearance of thrombus was delayed for the perfusion at 10 ml min 21 , while it was not affected at 3 ml min
21
( Fig. 2A and B, 40% dilution). Conversely, subsequent growth of thrombus was more affected at 3 ml min 21 than at 10 ml min 21 . Adding vWF to diluted whole blood accelerated intracapillary thrombus formation with perfusion at 10 ml min 21 , but not 3 ml min 21 ( Fig. 2A and B, vWF) . PCC seemed to increase thrombus growth particularly near the capillary wall (i.e. mural thrombus) at both flow rates ( Fig. 2A and B, PCC) . Addition of fibrinogen concentrate also led to thicker mural thrombus formation, but did not cause complete capillary occlusion ( Fig. 2A and B, Fgn) . The thickness of mural thrombus was further increased with fibrinogen in combination with PCC at both flow rates, but was more clearly demonstrated at 3 ml min 21 ( Fig. 2A and B, PCC and Fgn).
The immunostained thrombus examined by confocal microscopy demonstrated that the thrombus was composed of platelets (in green) containing abundant fibrin fibres (in red) (Fig. 3) . Although abundant platelets and fibrin deposition were confirmed in control samples at both flow rates, thick fibrin fibres were frequently observed at 10 ml min 21 relative to 3 ml min 21 ( Fig. 3A and B, control) . In addition, fibrin fibres and platelet thrombus formed at 10 ml min 21 seemed to follow the direction of flow. After 40% dilution with saline, thinner fewer fibrin fibres were seen at both flow rates, but the decrease was more obvious at 3 ml min 21 ( Fig. 3A and B, 40% dilution). Adding vWF increased platelets in the thrombi at 10 ml min 21 , not at 3 ml min 21 ( Fig. 3A and B, vWF) in agreement with the results of video microscopy ( Fig. 2) . On the other hand, images revealed that there was an abundance of fibrin fibres after PCC or fibrinogen intervention (Fig. 3A and B, PCC and Fgn, respectively). Increased deposition of thick fibrin fibres was observed after fibrinogen, whereas densely packed fibrin fibres were increased after PCC. These changes were more clearly shown at 3 ml min 21 than at 10 ml min 21 .
Western blot analysis of the thrombus formed in control blood showed considerable amounts of thrombin inside the thrombus at both 10 and 3 ml min 21 (Fig. 4A) . After 40% dilution, decreased thrombin was observed at both flow rates. Addition of PCC to diluted blood enhanced the amount of thrombin in the thrombus at both flow rates, while there were no significant changes after supplementing vWF. There were more abundant thrombin-catalysed fibrin species (a, b, g-chains and g-dimers) in thrombus formed at 3 ml min 21 compared with 10 ml min
( Fig. 4B ). After dilution, these fibrin chains were decreased at both flow rates. The decreases in fibrin after dilution were reversible with the addition of fibrinogen at 3 ml min 21 . The combination of PCC and fibrinogen increased both thrombin and fibrinogen contents at both flow rates.
Flow pressure changes during thrombus formation
Representative flow pressure changes in the capillary are shown in Figure 5A . Both onset (T on ) and growth (T 80 ) of thrombus formation took longer at 3 ml min 21 relative to 10 ml min 21 in undiluted control blood. After 40% dilution, both T on and T 80 were prolonged at both flow rates (P,0.05) ( Fig. 5B and C) , but the changes of T on and T 80 relative to baseline values were greater at 10 ml min 21 than at 3 ml min 21 (+96 vs +40% for T on ; +85 vs +50% for T 80 ). In diluted whole blood, T on was shortened by 38% with vWF at 10 ml min 21 (P,0.05 vs 40% dilution), but not at 3 ml min 21 . Conversely, T 80 , but not T on , was improved by PCC only at the lower flow rate. After adding fibrinogen, T 80 was prolonged at both flow rates (P,0.05 vs 40% dilution). Prolonged T 80 with fibrinogen replacement at both flow rates was partially restored by the combination of PCC and fibrinogen. In particular, T on at 3 ml min 21 was shortened by 45% after adding PCC to fibrinogen (P,0.05 vs fibrinogen).
Thromboelastometry
After 40% dilution, MCF was decreased (Table 1 ) (P,0.05).
Compared with the results from flow assays, the interventions with vWF and PCC in diluted blood did not improve any thromboelastometric parameters. On the other hand, fibrinogen and the combination of PCC and fibrinogen improved MCF (P,0.05, respectively, vs 40% dilution). The initial appearance of thrombus at 3 ml min 21 was similar to perfusion at 10 ml min 21 , but subsequent growth of thrombus was slower at 3 ml min
21
. *Occlusion occurred in the capillary. After 40% dilution of whole blood, the initial appearance of thrombus was prolonged for perfusion at 10 ml min 21 , while it was not affected at 3 ml min 21 . Conversely, subsequent growth of thrombus was delayed at 3 ml min 21 more than at 10 ml min 21 .
Addition of vWF to diluted whole blood accelerated appearance of thrombus at 10 ml min 21 . Adding PCC increased both intra-luminal and mural thrombus formation at both flow rates. Addition of fibrinogen (Fgn) concentrate increased the thickness of mural thrombus, but did not cause the complete capillary occlusion.
Thrombus formation in whole blood from patients undergoing cardiac surgery
Blood cell counts and other coagulation values from cardiac surgical patients are summarized in Table 2 . Baseline laboratory values were within normal ranges. After CPB, haematocrit, platelet count, fibrinogen, prothrombin, and AT were significantly decreased from baseline (P,0.05). PT and aPTT were prolonged to 1.6-to 1.8-fold from baseline (P,0.05, respectively). On the other hand, FVIII levels were maintained, and vWF levels were above the baseline after CPB.
Thrombus formation under flow conditions before and after CPB
The results of video microscopic evaluation and flow pressure changes in whole blood from cardiac surgery patients were in agreement with results in the diluted healthy volunteer blood. After CPB, both deposition and subsequent growth of thrombi on the capillary at 3 ml min 21 were prolonged compared with baseline. This prolonged thrombus formation was shortened by adding PCC. Addition of fibrinogen concentrate to post-CPB samples increased the thickness of mural thrombus, but did not cause complete capillary occlusion. In combination with PCC, the thickness of thrombus was further increased with fibrinogen at 3 ml min 21 .
For flow pressure changes, T on and T 80 after CPB were prolonged by 102 and 78% from baseline, respectively (P,0.05) (Fig. 6) . Addition of PCC shortened both T on and T 80 at 3 ml min 21 (P,0.05 vs post-CPB), while addition of fibrinogen prolonged these parameters. Prolongations of T on and T 80 were decreased by adding PCC to fibrinogen. 
Thromboelastometry
In post-CPB samples, both CT EXTEM and CFT EXTEM tended to be prolonged compared with baseline (Table 3 ). In addition, both MCF EXTEM and MCF FIBTEM were decreased after CPB compared with baseline (P,0.05, respectively). In contrast to the results of flow experiments, addition of PCC alone at the end of CPB did not improve EXTEM parameters. On the other hand, improvements of parameters were shown in thromboelastometry clearly compared with the flow assay after adding fibrinogen. Fibrinogen not only shortened CT EXTEM and CFT EXTEM , but also increased MCF EXTEM and MCF FIBTEM (P,0.05, respectively).
Discussion
We demonstrated the influence of blood flow rates on the composition of thrombus (platelets, thrombin, fibrin, etc.), and procoagulant responses to different haemostatic components (vWF, PCC, and fibrinogen concentrate) added to diluted blood. Normal thrombus formation in vivo initially depends on vWF-mediated platelet adhesion in arterial flow. 26 Lower platelet count and vWF delayed the onset of thrombus formation after 40% in vitro haemodilution. The delay was more pronounced at 10 compared with 3 ml min 21 . Further, delayed thrombus formation after dilution was restored by adding vWF at 10 ml min 21 28 However, vWF activity is less prone to perioperative decreases compared with other coagulation factors including fibrinogen and prothrombin. In diluted blood, increasing vitamin K-dependent coagulation factors using PCC led to improved mural thrombus growth, which was . After 40% dilution, decreased amounts of thrombin were observed at both flow rates. The addition of PCC to diluted blood increased the amount of thrombin in the thrombus at both flow rates, while there were no significant changes after supplementing vWF. (B) Fibrin detection: there was more abundant thrombin-catalysed fibrin species (a-, b-, g-chains and g-dimers) in the thrombus formed at 3 compared with 10 ml min
21
. After dilution, these fibrin chains were decreased at both flow rates. The decreases in fibrin after dilution were reversible with fibrinogen replacement at 3 ml min 21 . The combination of PCC and fibrinogen increased both thrombin and fibrinogen content at both flow rates. Fgn, fibrinogen. more pronounced at 3 ml min 21 . These findings were corroborated by increased amounts of thrombin and fibrin formation within the thrombus on confocal microscopy and western blot analysis. Thus, PCC seems to increase the amount of thrombus-bound thrombin and mural fibrin formation, but intra-luminal thrombus growth is limited when blood flow (shear rate) is high (10 ml min 21 ). Increased mural thrombus formation could be the mechanism responsible for improved haemostasis after PCC administration, which has been documented in vivo using porcine dilutional coagulopathy models.
-31
Maintaining plasma fibrinogen is considered to be important for perioperative haemostasis. 32 33 In our study, video microscopic data revealed thickened thrombus along capillary walls at 3 ml min 21 after supplementing fibrinogen in diluted whole blood from healthy volunteers. In addition, western blot analysis showed that 40% dilution with saline caused decrease in fibrin a-and b-chains, and cross-linked fibrin (g-dimer) at the lower flow rate relative to the higher flow rate. Fibrin a-and b-chains were restored after fibrinogen replacement at 3 ml min 21 . In our flow-chamber system, intraluminal thrombus development is reflected in the rate of pressure increase. Interestingly, fibrinogen supplementation in both diluted volunteer blood and post-CPB blood resulted in delayed capillary occlusion, which was more extensive at the higher flow rate compared with the lower rate. Paradoxical dilution, both T on and T 80 were prolonged at both flow rates. Addition of vWF shortened T on at 10 ml min
21
, but not at 3 ml min 21 . PCC shortened T 80 at 3 ml min 21 . However, addition of fibrinogen to diluted whole blood prolonged T on at 10 ml min 21 and T 80 at both flow rates. After addition of both fibrinogen and PCC, T on at 3 ml min 21 was shortened by 46% compared with T on after 40% dilution. *P,0.05 vs control; **P,0.05 vs 40% dilution.
Fgn, fibrinogen. became more densely packed after fibrinogen was added. A rapid adsorption of thrombin to fibrin strands seems to be important in localizing thrombin activity 35 and limiting intravascular thrombus extension. 36 After severe haemodilution, thrombus formation is progressively disturbed because of the loss of multiple procoagulant factors and platelets. Therefore, combined therapies using different haemostatic products can be reasonable and efficacious interventions. 30 37 In our study, procoagulant effects of combined PCC and fibrinogen were differently shown by the flow experiments and thromboelastometry. In the flow assay, increased thickness of mural thrombus by fibrinogen plus PCC was demonstrated at both flow rates. On the other hand, increased fibrin polymerization was strongly reflected on thromboelastometry as fibrinogen replacement improved clot formation parameters more than combined PCC and fibrinogen alone (Tables 1 and 3 ). Indeed, Weber and colleagues have recently demonstrated that point-of-care test-guided transfusion of fibrinogen concentrate, PCC, and platelets for post-CPB bleeding can be superior to the conventional coagulation testing in terms of haemostatic efficacy and costeffectiveness. 23 There are several advantages of our microchip-based flowchamber system compared with conventional assays. The advantage of testing whole blood is the inclusion of rheological effects on haemostasis exerted by red blood cells. 14 15 Turitto and Weiss 14 demonstrated that the extent of platelet adhesion is inversely proportional to haematocrit. We have also demonstrated that 20% volume replacement of warfarin-treated whole blood with fresh-frozen plasma caused the dilution of erythrocytes and platelets, and paradoxically obtunded the onset of thrombus formation under flow conditions. 19 In this regard, flow-chamber testing can be considered more physiological as it includes dynamic interactions of both cellular and soluble elements of haemostasis. The limitations of our study are as follows. First, the flowchamber system does not reflect natural exposures of collagen, tissue factor, or both, nor does it include organ-specific endothelial responses (e.g. vasoconstriction). 38 39 Secondly, CTI is used to inhibit FXIIa and to prevent premature clotting of blood in the reservoir. 18 -20 It is plausible that CTI reduces thrombus formation by interfering with platelet-mediated FXIIa activation. 40 Finally, we used normal saline as the diluent of whole blood, and thus coagulation disturbances might have been more extensive than with other buffered crystalloids. 41 In addition, albumin was the only type of colloid used in the clinical part of the study. Further studies are thus needed to address the effects of different crystalloids and colloids on coagulation under flow conditions. In summary, our study highlights the contribution of blood flow to thrombus formation after haemodilution and subsequent haemostatic component interventions. Fibrin deposition was more extensively decreased by haemodilution under the lower flow rate compared with the higher flow rate. The amount of thrombin in the thrombus was decreased at both flow rates. Replacement of vWF accelerated intra-luminal thrombus formation at the higher flow rate, whereas fibrinogen concentrate was more efficient at the lower flow rate. The addition of PCC improved mural thrombus formation at both flow rates. Incorporating blood flow conditions is potentially useful in evaluating therapeutic efficacy of haemostatic agents (e.g. vWF and PCC) that involve platelet and plasma factor interactions.
